 OncoSec Medical Incorporated NASDAQ:ONCS the Company or OncoSec, a company developing late-stage intratumoral cancer immunotherapies, today announced that, based upon tumor regression and associated clinical responses observed in the heavily pretreated Cohort 1 of the KEYNOTE-890 study, the Company plans to expand into earlier first-line treatment to investigate the combination of OncoSecs lead product candidate TAVOTM plasmid-based interleukin-12 or pIL-12 and Mercks KEYTRUDA pembrolizumab plus chemotherapy in patients with inoperable locally advanced or metastatic triple negative breast cancer mTNBC. Cohort 2 will be added as a second arm to the ongoing KEYNOTE-890 study. 